Researchers call for more trials to examine body composition and weight maintenance during and after GLP-1RA therapy, and urge clinicians to provide diet and exercise guidance to sustain gains after cessation.

Current prescribing guidelines are inconsistent and may inadequately address post-treatment weight regain, with NICE recommending a two-year limit for semaglutide but not for tirzepatide.

The study highlights the need to understand body composition changes during and after treatment and notes that guidelines often fail to address weight regain after stopping GLP-1RAs.

A brake.

Common side effects include nausea, headaches, and diarrhea, affecting about one in ten users, with rare but serious pancreatitis reported in Wegovy users at low frequencies.

There is evidence of appetite suppression that can lead to rebound weight gain when the therapy is stopped.

A BMJ study of US veterans found starting GLP-1 injections is linked to a reduced risk of substance use disorders and related healthcare events, with larger benefits for those with prior SUDs; benefits appeared in both sexes, though the cohort was predominantly older men.

The medications work by mimicking hormones and have effects that last days, unlike natural hormones which break down quickly.

Many users discontinue therapy early due to GI side effects, cost, insurance coverage limits, and access barriers; roughly half of initiators stop therapy.

Approximately half of participants initiating GLP-1 weight-loss therapy discontinue prematurely because of side effects, cost, and insurance or prescribing barriers, undermining long-term weight loss.

Experts note that about half of patients discontinue early due to GI side effects, cost, and insurance or prescribing barriers, limiting long-term effectiveness.

Long-term data are lacking; real-world long-term outcomes beyond theoretical projections are not yet established.